ProSomnus Sleep Technologies devices will be showcased in at least six poster abstracts at the upcoming virtual AADSM (American Academy of Dental Sleep Medicine) Annual Meeting, April 30-May 2. ProSomnus is committed to evidence-based research that enables clinicians to provide the best patient experiences and outcomes for OSA therapy.

Highlighted posters include:

  1. “Case Study on Toughness of Multiple Devices with a Severe Bruxing Patient” by Neal Seltzer, DMD; Gina Pepitone-Mattiello, RDH; Keith Batcheller, BS, MA
  2. “Device Design’s Impact on Dose in Oral Appliance Therapy” by Mark T. Murphy, DDS D-ABDSM; Kimberly Munro, Facility Manager
  3. “The Costs of OSA Treatments: Is OAT More Expensive?” By Len Liptak, MBA
  4. “OAT Device Selection: Characterizing Custom OAT Device Designs and Materials” by Jerry Hu DDS, D-ABDSM, D-ASBA, D-ACSDD; Len Liptak, MBA
  5. “What Do We Know About Sleep Medicine Physicians’ Preferences Toward OAT?” by Len Liptak, MBA
  6. “Precision Oral Appliance Therapy: The Prime – Time Treatment for OSA” by Edward T. Sall, MD, DDS, MBA

“ProSomnus proudly supports research that investigates the performance of precision oral appliances for the treatment of obstructive sleep apnea,” says Len Liptak, ProSomnus CEO and co-founder, in a release. “Precision oral appliances feature qualities that are different from traditional oral appliances. Research is essential for helping sleep physicians and dental sleep providers understand how these differences improve the safety, effectiveness and economics of treating obstructive sleep apnea.”

Dave Kuhns, PhD, chief science officer at ProSomnus, in a release, “We have coordinated with leading key opinion leaders and dental sleep medicine Diplomates to publish studies demonstrating that the use of a precision oral appliance significantly affects the success of their treatments. Furthermore, in our [Institutional Review Board] preference study, the researchers enrolled a broad range of patients and comparative devices to enable a confident determination of preference. Many thanks to these experienced doctors.”

Lead faculty clinician for ProSomnus Mark T. Murphy, DDS, DABDSM, says in a release, “It is indeed exciting for medical and dental professionals to share the success of oral appliance therapy in this way. Efficacy, adherence, and now dose management all align with cost effectiveness to facilitate physician acceptance of this treatment for mild and moderate OSA as outlined in the guidelines.”